The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Abstract
OBJECTIVES: Amyloid-beta(42) (Abeta(42)) appears central to Alzheimer's disease (AD) pathogenesis and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Abeta(42) is decreased in dementia of the Alzheimer's type. This decrease may reflect plaques acting as an Abeta(42) "sink," hindering transport of soluble Abeta(42) between brain and CSF. We investigated this hypothesis. METHODS: We compared the in vivo brain amyloid load (via positron emission tomography imaging of the amyloid-binding agent, Pittsburgh Compound-B [PIB]) with CSF Abeta(42) and other measures (via enzyme-linked immunosorbent assay) in clinically characterized research subjects. RESULTS: Subjects fell into two nonoverlapping groups: those with positive PIB binding had the lowest CSF Abeta(42) level, and those with negative PIB binding had the highest CSF Abeta(42) level. No relation was observed between PIB binding and CSF Abeta(40), tau, phospho-tau(181), plasma Abeta(40), or plasma Abeta(42). Importantly, PIB binding and CSF Abeta(42) did not consistently correspond with clinical diagnosis; three cognitively normal subjects were PIB-positive with low CSF Abeta(42), suggesting the presence of amyloid in the absence of cognitive impairment (ie, preclinical AD). INTERPRETATION: These observations suggest that brain amyloid deposition results in low CSF Abeta(42), and that amyloid imaging and CSF Abeta(42) may potentially serve as antecedent biomarkers of (preclinical) AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The continuous relationship between CSF Aβ42 and amyloid PET, however, is “L-shaped” rather than linear [116,117,120].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [120]
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [18]
In the citing paper
“Since people with brain amyloid deposition have low CSF Aβ42 (Fagan et al., 2006), this strongly suggests that amyloid deposition on average is beginning earlier in apoE4-positive subjects.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Fagan et al., 2006
In the citing paper
“Since people with brain amyloid deposition have low CSF Aβ42 (Fagan et al., 2006), this strongly suggests that amyloid deposition on average is beginning earlier in apoE4-positive subjects.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Fagan et al., 2006
In the citing paper
“Antemortem diagnosis also relies heavily on the presence of Aβ and tau, either as measured in the spinal fluid or imaged using positron emission tomography (PET) [7–10].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [9]
In the citing paper
“Levels of CSF Aβ42 are typically reduced in dementia of the Alzheimer type (DAT),8-11 reflecting its aggregation and deposition as amyloid in the brain,12”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [12]
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationProfound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“icant neuronal loss in vulnerable regions, such as the entorhinal cortex.(19) However, cognitively normal individuals with neuropathological AD (preclinical AD) do not demonstrate such neuronal loss,(20) and we observed reduced CSF A 42 levels in three cognitively normal subjects.”
BackgroundSelf-citationKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513
Self-citationCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
Self-citationValidation of clinical diagnostic criteria for Alzheimer's disease
Morris, J. C., McKeel, D. W., Fulling, K., Torack, R. M., & Berg, L. (1988) · Annals of Neurology · doi:10.1002/ana.410240105 · Cited by 362
Self-citationHULETTE, C. M., WELSH-BOHMER, K. A., MURRAY, M. G., SAUNDERS, A. M., MASH, D. C., & MCINTYRE, L. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199812000-00009 · Cited by 311
Research works printed but not linked: 21
- 10.1016/S0925-4439(00)00031-4 · DOI
- 10.1001/archneur.55.3.326 · DOI · Paper page
- 10.1001/archneur.58.3.397 · DOI
- 10.1002/ana.20009 · DOI · Paper page
- 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X · DOI
- 10.1021/jm030026b · DOI
- 10.1016/B978-012389760-2/50028-1 · DOI
- 10.1097/00004647-199609000-00008 · DOI
- 10.1038/sj.jcbfm.9600146 · DOI
- Price J, 2005, PIB PET amyloid imaging in Alzheimer's disease and mild cognitive impairment, J Nucl Med, 46, 123P
- 10.1001/archneur.58.11.1803 · DOI
- 10.1046/j.1471-4159.2002.00889.x · DOI
- 10.1001/archneur.58.9.1395 · DOI · Paper page
- 10.1111/j.1532-5415.2004.52459.x · DOI
- 10.1126/science.1067568 · DOI · Paper page
- 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A · DOI
- 10.1212/01.WNL.0000091890.32140.8F · DOI · Paper page
- 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X · DOI
- 10.1212/WNL.59.7.1034 · DOI
- 10.1212/01.wnl.0000172919.50001.d6 · DOI
- 10.1172/JCI200317527 · DOI
Cited by
Sorted by citations
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
“CSF Aβ42 and PET measures of fibrillar Aβ are strongly and inversely correlated with one another, and appear to reflect Aβ deposition in the brain [17].”
BackgroundSelf-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Metadata
- Authors
- Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., DeKosky, S. T., Morris, J. C., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- University of Pittsburgh (US)
- Corresponding author
- Fagan, Anne M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-02-17
- Volume
- 59
- Issue
- 3
- Pages
- 512-519
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2006858320
- Cited by
- 1,246
- References
- 8
- Citations by year
- 2026: 16 · 2025: 30 · 2024: 37 · 2023: 35 · 2022: 40 · 2021: 45 · 2020: 77 · 2019: 56 · 2018: 50 · 2017: 67 · 2016: 71 · 2015: 69 · 2014: 65 · 2013: 94 · 2012: 76
- FWCI
- 27.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG03991, AG 05681, AG026276, P50AG005681, P01AG003991, P01AG026276)
- National Institute of Neurological Disorders and Stroke (P30NS048056)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- amyloid-beta 42, cerebrospinal fluid biomarkers, Pittsburgh compound B, amyloid plaques, Alzheimer's disease, preclinical Alzheimer's disease, amyloid imaging, tau protein, phosphorylated tau, plasma amyloid-beta, cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Diagnostic Imaging, Female, Humans, Image Processing, Computer-Assisted, Male, Memory, Middle Aged, Neuropsychological Tests, Peptide Fragments, Tissue Distribution, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
